Non-Alcoholic Fatty Liver Disease Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutic

Non-Alcoholic Fatty Liver Disease Pipeline constitutes 90+ key companies continuously working towards developing 100+ Non-Alcoholic Fatty Liver Disease treatment therapies, analyzes DelveInsight.

Non-Alcoholic Fatty Liver Disease Overview:

Non-alcoholic fatty liver disease (NAFLD) is a term that encompasses a range of conditions characterized by hepatic steatosis, as detected through imaging or histology (macro-vesicular steatosis), without secondary causes such as excessive alcohol intake, long-term use of certain medications, or genetic disorders. In Western countries, NAFLD affects approximately 20-30% of the population.

It is closely linked to obesity, diabetes, dyslipidemia, insulin resistance, and metabolic syndrome. Additionally, studies have shown a correlation between exposure to inorganic arsenic and NAFLD, indicated by elevated alanine transferase (ALT) levels. Due to its strong association with metabolic syndrome, NAFLD is also linked to cardiovascular risk factors, which contribute to mortality alongside complications like end-stage liver cirrhosis and hepatocellular carcinoma.

Request for a detailed insights report on Non-Alcoholic Fatty Liver Disease pipeline insights @ https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Non-Alcoholic Fatty Liver Disease Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Non-Alcoholic Fatty Liver Disease Therapeutics Market.

Key Takeaways from the Non-Alcoholic Fatty Liver Disease Pipeline Report

DelveInsight's Non-Alcoholic Fatty Liver Disease pipeline report depicts a robust space with 90+ active players working to develop 100+ pipeline therapies for Non-Alcoholic Fatty Liver Disease treatment.
In December 2024, Galectin Therapeutics shared results from its global NAVIGATE clinical trial, which evaluates belapectin for patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis and portal hypertension.
In October 2024, PharmaIN Corporation announced plans to present interim results from its ongoing Phase I trial of PHIN-214, a lead candidate for preventing and treating decompensated cirrhosis.
In June 2024, Resolution Therapeutics Limited, in collaboration with the University of Edinburgh, presented key data on RTX001 at EASL Congress 2024 in Milan, highlighting the potential of macrophage cell therapy for advanced liver cirrhosis.
In June 2024, Lipocine's Phase II results on LPCN 1148 in cirrhosis were featured in a late-breaking oral presentation at the EASL Congress 2024 in Milan.
In April 2024, LyGenesis dosed the first patient in its Phase IIa trial for an allogenic regenerative cell therapy, designed to be transplanted into lymph nodes as a potential treatment for end-stage liver disease (ESLD).
In March 2024, Lipocine announced positive topline results from a Phase II trial of LPCN 1148, an oral therapy under development for managing liver cirrhosis.
Key Non-Alcoholic Fatty Liver Disease companies such as Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel, Inventiva Pharma, Galectin Therapeutics, AngioLab, MediciNova, AstraZeneca, and others are evaluating new drugs for Non-Alcoholic Fatty Liver Disease to improve the treatment landscape.
Promising Non-Alcoholic Fatty Liver Disease pipeline therapies in various stages of development includeLanifibranor, ZED 1227, TVB-2640, ALS-L1023, AZD9550, and others.

Non-Alcoholic Fatty Liver Disease Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Non-Alcoholic Fatty Liver Disease Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Alcoholic Fatty Liver Disease treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Non-Alcoholic Fatty Liver Disease market.

Download our free sample page report on Non-Alcoholic Fatty Liver Disease pipeline insights @ https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Non-Alcoholic Fatty Liver Disease Emerging Drugs

Lanifibranor: Inventiva Pharma
ZED 1227: Dr. Falk Pharma GmbH
TVB-2640: Sagimet Biosciences
ALS-L1023: AngioLab
AZD9550: AstraZeneca

Non-Alcoholic Fatty Liver Disease Companies

Around 90+ major companies are actively developing therapies for Non-Alcoholic Fatty Liver Disease (NAFLD). Among them, Inventiva Pharma has a drug candidate in the most advanced stage of development, Phase III.

DelveInsight's report covers around 100+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Non-Alcoholic Fatty Liver Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Non-Alcoholic Fatty Liver Disease Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Non-Alcoholic Fatty Liver Disease Therapies and Key Companies: Non-Alcoholic Fatty Liver Disease Clinical Trials and advancements @ https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Non-Alcoholic Fatty Liver Disease Pipeline Therapeutic Assessment
• Non-Alcoholic Fatty Liver Disease Assessment by Product Type
• Non-Alcoholic Fatty Liver Disease By Stage
• Non-Alcoholic Fatty Liver Disease Assessment by Route of Administration
• Non-Alcoholic Fatty Liver Disease Assessment by Molecule Type

Download Non-Alcoholic Fatty Liver Disease Sample report to know in detail about the Non-Alcoholic Fatty Liver Disease treatment market @ Non-Alcoholic Fatty Liver Disease Therapeutic Assessment @ https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Non-Alcoholic Fatty Liver Disease Current Treatment Patterns
4. Non-Alcoholic Fatty Liver Disease - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Non-Alcoholic Fatty Liver Disease Late-Stage Products (Phase-III)
7. Non-Alcoholic Fatty Liver Disease Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Non-Alcoholic Fatty Liver Disease Discontinued Products
13. Non-Alcoholic Fatty Liver Disease Product Profiles
14. Non-Alcoholic Fatty Liver Disease Key Companies
15. Non-Alcoholic Fatty Liver Disease Key Products
16. Dormant and Discontinued Products
17. Non-Alcoholic Fatty Liver Disease Unmet Needs
18. Non-Alcoholic Fatty Liver Disease Future Perspectives
19. Non-Alcoholic Fatty Liver Disease Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Non-Alcoholic Fatty Liver Disease Pipeline Reports Offerings: https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.